DEF: PAVmed Inc. Seeks Stockholder Approval for Equity Plan Amendment and Stock Issuance at Upcoming Annual Meeting

PAVmed Inc. is soliciting proxies for its annual meeting on June 18, 2025, to vote on key proposals including director elections, stock issuance approval, an equity plan amendment, executive compensation, and auditor ratification.

Summary

• PAVmed Inc. will hold its annual meeting of stockholders on June 18, 2025, virtually.
• Stockholders will vote on six proposals, including the election of two Class C directors, approval of stock issuance related to pre-funded warrants, an amendment to the 2014 Long-Term Incentive Equity Plan, an advisory vote on executive compensation, and ratification of the appointment of CBIZ CPAs as the company's independent auditor.
• The Board recommends voting FOR all management proposals.
• The record date for determining stockholders eligible to vote is April 22, 2025.
• The company is seeking approval to increase the number of shares available under the 2014 Plan by 2,500,000 shares, from 2,412,140 to 4,912,140.
• In February 2025, the company sold shares and pre-funded warrants in a private placement, and is now seeking stockholder approval for the issuance of shares upon exercise of these warrants.
• The company's common stock is traded on the Nasdaq Capital Market under the symbol PAVM.
• The company has temporarily suspended participation in the Employee Stock Purchase Plan (ESPP) effective September 2024.
• The company's executive officers and directors have fiduciary obligations to other companies, which may present conflicts of interest.
• The company's independent directors are Michael J. Glennon, Timothy E. Baxter, Ronald M. Sparks, and Debra J. White.
• The company has a code of ethics applicable to all executive officers, directors, and employees.
• The company's insider trading policy prohibits short-term trading, short sales, transactions in derivatives of, and hedging of the company's securities by its directors, executive officers, employees and designated consultants, and prohibits pledging of the company's securities by them.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, presenting information in a neutral and factual manner. The proposals are generally routine, and the Board's recommendations are clear. The sentiment is slightly positive due to the company's efforts to seek stockholder input and ensure compliance with regulations.

Positives

• The Board is actively seeking stockholder input on key decisions through the proxy vote.
• The company is taking steps to ensure compliance with Nasdaq listing rules and SEC regulations.
• The company has a code of ethics and insider trading policy in place.
• The company is providing a broad-based equity compensation program to attract and retain highly skilled people.

Negatives

• The company's executive officers and directors have fiduciary obligations to other companies, which may present conflicts of interest.
• The company has temporarily suspended participation in the Employee Stock Purchase Plan (ESPP) effective September 2024.
• The company's insider trading policy prohibits short-term trading, short sales, transactions in derivatives of, and hedging of the company's securities by its directors, executive officers, employees and designated consultants, and prohibits pledging of the company's securities by them.

Risks

• Failure to obtain stockholder approval for the stock issuance proposal could negatively impact the company's and Veris' ability to raise capital in the future.
• The issuance of shares pursuant to the Pre-Funded Warrants will have a dilutive effect on the existing stockholders, including on the voting power and economic rights of the existing stockholders, and may result in a decline in the price of the company's common stock or in greater price volatility.
• Conflicts of interest may arise due to the fiduciary obligations of officers and directors to other companies.
• The company is subject to Section 203 of the DGCL, an anti-takeover statute, which could make it more difficult to acquire the company.

Future Outlook

The company plans to make equity grants in connection with new hires and promotions and in connection with its annual employee reviews.

Industry Context

The document reflects standard corporate governance procedures for publicly traded companies, including proxy solicitations, executive compensation disclosures, and related party transaction reporting, all within the context of the medical device industry.

Comparison to Industry Standards

• The executive compensation structure, including base salary, bonus potential, and equity awards, is typical for companies of similar size and stage in the medical device industry.
• The use of a classified board and anti-takeover provisions is a common practice among publicly traded companies to protect shareholder interests and ensure fair value in the event of a potential acquisition.
• The company's reliance on related party transactions, particularly with its subsidiary Lucid Diagnostics, is not uncommon for companies with complex organizational structures, but requires careful scrutiny and independent oversight to ensure fairness and transparency.
• The company's auditor fees of $691,000 in 2024 and $864,000 in 2023 are within the range of what is expected for a company of similar size and complexity.

Related Party Transactions

• Lucid Diagnostics is party to a management services agreement with PAVmed, where PAVmed provides management and oversight of Lucid's activities.
• PAVmed and Lucid entered into a payroll and benefit expense reimbursement agreement.
• PAVmed and Lucid entered into a license agreement for intellectual property rights relating to esophageal ablation device technology.
• PAVmed entered into a strategic advisor agreement with Dr. Sundeep Agrawal, who later became a director.
• PAVmed consummated the exchange of Convertible Notes for Series C Preferred Stock with Alto Opportunity Master Fund, SPC Segregated Master Portfolio B.
• PAVmed consummated the sale of Series C Preferred Stock to Alto Opportunity Master Fund, SPC Segregated Master Portfolio B.

Stakeholder Impact

• Approval of the stock issuance proposal will allow the company to issue shares, potentially diluting existing stockholders but also providing capital for growth.
• The equity plan amendment aims to attract and retain employees, potentially benefiting employees and shareholders through increased company performance.
• The Say on Pay proposal allows stockholders to express their opinion on executive compensation, influencing future compensation decisions.
• The Accountant Ratification Proposal ensures the company has an independent auditor, providing assurance to stakeholders regarding financial reporting.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will hold its annual meeting on June 18, 2025, to discuss and vote on the proposals.
• The company will continue to seek stockholder approval of the stock issuance proposal until it obtains such approval.

Key Dates

Keywords

proxy statement, annual meeting, stock issuance, equity plan, executive compensation, director election, PAVmed, CBIZ CPAs, pre-funded warrants, Nasdaq